Canaccord analyst Sumant Kulkarni raised the firm’s price target on Definium Therapeutics (DFTX) to $38 from $25 and keeps a Buy rating on the shares. The firm believes the shares represent a significant opportunity heading into DT120 Phase 3 data for depression in late Q2. They believe shares of Definium Therapeutics could be up 50% or more on a solid Emerge result.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DFTX:
- Definium Therapeutics initiated with an Overweight at Piper Sandler
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial
- Definium Therapeutics announces publication of study on general anxiety disorder
- Mind Medicine Readies for Data-Rich 2026 Pivot
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results